Infliximab: a review of its use in Crohn's disease and rheumatoid arthritis.
about
Effects of inhibition of interleukin-6 signalling on insulin sensitivity and lipoprotein (a) levels in human subjects with rheumatoid diseasesImmune system of the inner ear as a novel therapeutic target for sensorineural hearing lossSubcompartments of the macrophage recycling endosome direct the differential secretion of IL-6 and TNFalpha.Infliximab in the treatment of Crohn's disease.A trans-Golgi network golgin is required for the regulated secretion of TNF in activated macrophages in vivoAdora2b adenosine receptor signaling protects during acute kidney injury via inhibition of neutrophil-dependent TNF-α releaseThe use of TNF-alpha blocking agents in rheumatoid arthritis: an update.Circulating T cells to infliximab are detectable mainly in treated patients developing anti-drug antibodies and hypersensitivity reactionsPopulation pharmacokinetic analysis of infliximab in patients with ulcerative colitis.A review of CT-P13: an infliximab biosimilar.Progress in biosimilar monoclonal antibody development: the infliximab biosimilar CT-P13 in the treatment of rheumatic diseases.Tumour necrosis factor inhibitors and infection: What is there to know for infectious diseases physicians?Safety Profile of Anticancer and Immune-Modulating Biotech Drugs Used in a Real World Setting in Campania Region (Italy): BIO-Cam Observational StudyInfliximab in ulcerative colitis.How the immune system responds to therapeutic biological agents.Reduction of the HIV-1 reservoir in resting CD4+ T-lymphocytes by high dosage intravenous immunoglobulin treatment: a proof-of-concept study.Infliximab for the treatment of ulcerative colitis.Selective TNF-α targeting with infliximab attenuates impaired oxygen metabolism and contractile function induced by an acute exposure to air particulate matter.Oral administration of Parabacteroides distasonis antigens attenuates experimental murine colitis through modulation of immunity and microbiota composition.PhenotypicIn VivoScreening to Identify New, Unpredicted Indications for Existing Drugs and Drug Candidates
P2860
Q28744267-E907141E-9FE8-4EEB-A530-F345B5E55584Q30430796-0C942F98-46E9-485E-B5A5-BBB2640BA437Q30480503-5EA4A919-C0C1-4AF0-860A-C2D2A5A9BEC0Q35919228-BDD85AE4-F28A-4CE8-9180-169F78F1D527Q36491396-930D502A-E59F-4F2B-9951-B7A8633B9358Q36836965-17034CF2-E428-4804-B2E4-AC4A0A19A0ECQ36916918-59BF516A-2705-4B10-9F70-362F5808153FQ37412095-8D4CAE5C-95F5-4729-B42D-210D54555E00Q37424635-20800624-1D21-406A-A249-5F2F1F22F34AQ38203821-60DA2120-597C-49BA-B8B1-637A09F54312Q38365041-1D38473D-C8C1-4A7E-ACDB-E94BEE5CC30DQ40672157-6303A831-2778-4D70-80ED-C02B68E91625Q41439263-BDAE629A-0F43-4855-881D-FBD4514A3024Q41860347-88BAF579-508D-4473-8F69-8AA6EE45AD7BQ41882370-FFDCDD58-97D8-450E-851E-8A2C2101879FQ42551648-4644C615-A523-4E5E-A434-8637A38B673FQ47682064-2D893861-C0A4-47B8-8B60-617A4BAA56F0Q50981967-78E72403-54B8-4ED8-AD5C-C4706A3BCEF0Q51614351-CF4957F2-FC06-4E63-89EC-73B3C757E9ABQ56610263-EC7FCEAB-76FB-4A5B-952D-8D21E6C8B132
P2860
Infliximab: a review of its use in Crohn's disease and rheumatoid arthritis.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Infliximab: a review of its use in Crohn's disease and rheumatoid arthritis.
@ast
Infliximab: a review of its use in Crohn's disease and rheumatoid arthritis.
@en
type
label
Infliximab: a review of its use in Crohn's disease and rheumatoid arthritis.
@ast
Infliximab: a review of its use in Crohn's disease and rheumatoid arthritis.
@en
prefLabel
Infliximab: a review of its use in Crohn's disease and rheumatoid arthritis.
@ast
Infliximab: a review of its use in Crohn's disease and rheumatoid arthritis.
@en
P1433
P1476
Infliximab: a review of its use in Crohn's disease and rheumatoid arthritis.
@en
P2093
M Asif A Siddiqui
P304
P356
10.2165/00003495-200565150-00014
P577
2005-01-01T00:00:00Z
P6179
1015187996